All enrolled participants detected with anemia (Hb ≥ 8 and ≤ 11 gm/dL) [40] in both arms of the trial are eligible for the therapeutic IFA dosage to control iron deficiency anemia (tablets containing 20 mg elemental iron, 20 tablets/month for 5 months). The gene discussed is GSTM1; the disease is anemia.